Program areas at GAVI
the Vaccine goal: introduce and scale up vaccineswith the exception of pentavalent Vaccine, in aggregate all gavi-supported vaccines had higher coverage in 2023 than before the pandemic in 2019.- 34 gavi-supported Vaccine introductions and preventive campaigns took place in 2023 in addition to 40 outbreak response vaccination campaigns supported by Gavi.- 14 million girls fully immunized against hpv with Gavi support in 2023 more than the previous ten years combined.- 15 countries accessed cholera, meningococcal and yellow fever vaccines through gavi-supported emergency stockpiles a total of 29 times in 2023.- 57 gavi-supported countries increased breadth of protection with vaccines in the Gavi portfolio to 56%, up 3 percentage points from 2022.the equity goal: strengthen health systems to increase equity in immunizationin Gavi 5.0/5.1, health system strengthening (hss) support prioritizes equity in immunisation delivery, to reduce the number of zero-dose and under-immunized children.- >69 million children were reached with gavi-supported routine vaccines in 2023 more than in any year apart from 2019.- 47 countries have installed more than 67,000 cold chain equipment (cce) units procured by unicef supply division through Gavi's cold chain equipment optimization platform (cceop) nearly 5,200 in 2023 alone.- after several years of decline since 2019, average coverage of dtp3 in 26 low-income countries supported by Gavi held steady in 2023 the only income group to avoid decline.- 32 countries were approved for equity accelerator fund (eaf) funding to identify and reach zero-dose children and missed communities.- in 2023, gavi-supported countries maintained dtp3 coverage at 80% (compared to the 84% global average).the sustainability goal: improve sustainability of national immunization programsthe year 2023 confirmed the robustness of the Vaccine Alliance's co-financing approach and the steady financial commitment of countries, despite many countries facing increasing fragility.- us$ 215 million was contributed by countries towards the co-financing of gavi-supported vaccines in 2023 the highest amount yet and a testament to country ownership and the long-term financial sustainability of gavi-supported vaccines.- 55 Vaccine programs originally introduced with Gavi funding are now self-financed by countries as of 2023, up from 40 in 2018.- 100% of countries fully met their 2023 co-financing obligation except four waivers for humanitarian crisis.- in the face of fiscal challenges, climate change, conflict and instability, most gavi-supported countries maintained or increased domestic resources for co-financing of gavi-supported vaccines in 2023, bringing to us$ 1.7 billion their total contribution since the introduction of the co-financing policy in 2008.the healthy markets goal: ensure healthy markets for vaccines and related productsgavi's market shaping efforts make life-saving vaccines and other immunisation products more accessible and affordable for lower-income countries.- 10 markets for vaccines and immunisation products exhibited acceptable levels of healthy market dynamics in 2023, meeting the target for the year.- 10 innovative products were within the pipeline of commercial-scale manufacturers in 2023, continuing to exceed the Alliance target of 8 by 2025 well ahead of schedule..- 1 new product with improved characteristics was newly offered to gavi-supported countries in 2023, keeping the Alliance on track for its 2025 target: multivalent meningococcal conjugate Vaccine (mmcv), the first conjugate Vaccine to protect against the five predominant serogroups of meningococcal meningitis in africa.- through Gavi's market shaping efforts, the number of manufacturers supplying prequalified gavi-supported vaccines remained at 19 in 2023 (with more than half based in low- and middle-income countries) compared with 5 in 2001.further information on Gavi's progress towards achieving its strategic goals can be found in its 2023 annual progress report, online at: httpswwwgaviorgprogrammesimpactou...
Covax closed on 31 december 2023, after having delivered nearly 2 billion covid-19 Vaccine doses and safe injection devices to 146 economies, and is estimated to have averted over 2.7 million deaths in amc lower-income participating economies. Covax supplied 74% of low-income countries' covid-19 Vaccine doses during the pandemic; and in total, 54 of the 92 amc-eligible economies relied on covax for more than half of their covid-19 Vaccine supply. Covax helped lower-income countries achieve two-dose coverage of 57%, compared to the global average of 67%; and protect high-risk populations: 85% of health care workers and 72% of older adults (compared to high-income countries at 89% and 95%, respectively).further information on Gavi's covax report can be found in its 2023 annual progress report, online at: httpswwwgaviorgprogrammesimpactou...